Bloomberg, August 19, 2011 Teva Pharmaceutical Industries Ltd. (TEVA), the world’s biggest generic-drug maker, sold the anesthetic propofol in a way that led some patients to develop hepatitis C, a lawyer said at the start of a second trial over the allegations. (Robert Eglet featured in article.)
News
2nd Day of Testimony: Robert Eglet Continues Questioning Teva Pharmaceuticals Vice President
PR Newswire, August 24, 2011 — In a stunning turn in the Anne Arnold Hepatitis C trial in Clark County, Attorney Robert Eglet told the jury that production of the sedative Propofol was stopped within 3 weeks of the unprecedented $500 million verdict in the Chanin trial in May 2010. Teva Vice President, Craig Lea admits […]
Both Sides Point Fingers in Opening Statements in Hep C Trial
8 News Now, August 19, 2011 — A second trial in the hepatitis C outbreak is underway at the Regional Justice Center. A jury must decide whether drug companies are responsible for patients contracting the incurable liver disease at endoscopy clinics that used dangerous injection practices. (Robert Eglet featured in article.)
New Civil Trial Starts in Hepatitis C Case
Las Vegas Review-Journal, August 18, 2011 — A lawyer for hepatitis C patients suing two drug companies over an outbreak in Las Vegas told a jury Thursday that company officials purposely sold large containers of an anesthetic to clinics despite knowing it might lead nurses to reuse and contaminate the vials. (Robert Eglet featured in article.)
